Buccal Drug Delivery Systems Market Size

Buccal Drug Delivery Systems Market Size

Buccal Drug Delivery Systems Market size was valued at around USD 3.9 billion in 2023 and is estimated to grow at 8.6% CAGR from 2024 to 2032. Buccal drug delivery systems involve administering a drug through the buccal mucosa (the lining of the cheek) to achieve systemic or local effects. This method utilizes the mucous membrane inside the mouth to absorb the drug directly into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism in the liver.

To get key market trends

  Download Free Sample

The market is gaining traction due to its ability to enhance drug bioavailability, improve patient compliance, and accommodate ongoing advancements in pharmaceutical drug delivery technologies. The rising prevalence of chronic diseases and a supportive regulatory landscape further bolster its market growth. A key driver for buccal drug delivery systems is the enhanced bioavailability achieved through this route. Buccal administration increases drug bioavailability by bypassing the gastrointestinal tract and hepatic first-pass metabolism, allowing more drug to enter systemic circulation. Additionally, it is non-invasive and easy to administer, improving compliance among those who have difficulty swallowing pills, such as pediatric and geriatric patients.
 

Moreover, the increasing incidence of chronic diseases, such as cardiovascular diseases and diabetes, which require long-term medication, is also driving the demand for alternative drug delivery systems like buccal routes that offer sustained and controlled drug release.